AC-480

N/A

Report date: 2026/05/12 20:00:17
NME

Base Information

Drug NameAC-480
Drug Alias NameAC-480BMS-599626
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEpidermal growth factor receptor erbB1 inhibitorsReceptor protein-tyrosine kinase erbB-2 inhibitorsReceptor tyrosine-protein kinase erbB-3 inhibitors +[4] 
TargetsReceptor protein-tyrosine kinase erbB-4Epidermal growth factor receptor erbB1Receptor protein-tyrosine kinase erbB-2 +[4] 
Therapy Area/IndicationsSolid tumoursNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFranceSpain
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBristol Myers Squibb SrlcompanyNational Cancer InstituteDaiichi Sankyo Co Ltd
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasm MetastasisNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A